Nasus Pharma names Nir Sassi chief financial officer, effective November 11, 2026
The intranasal drug developer tapped a finance executive with past CFO roles at two Nasdaq companies as it prepares a pivotal Phase 3 study of its lead candidate NS002.
SEC filing